Other equities analysts also recently issued research reports about the stock. JPMorgan Chase & Co. reaffirmed a buy rating on shares of Celgene in a report on Saturday, February 18th. Cantor Fitzgerald set a $159.00 price objective on shares of Celgene and gave the stock a buy rating in a report on Saturday, February 18th. Credit Suisse Group AG set a $148.00 price objective on shares of Celgene and gave the stock a buy rating in a report on Saturday, February 18th. Oppenheimer Holdings Inc. set a $148.00 price objective on shares of Celgene and gave the stock a buy rating in a report on Saturday, February 25th. Finally, Jefferies Group LLC set a $154.00 price objective on shares of Celgene and gave the stock a buy rating in a report on Saturday, May 13th. One analyst has rated the stock with a sell rating, six have issued a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Celgene currently has an average rating of Buy and an average price target of $138.89.
Shares of Celgene (NASDAQ:CELG) opened at 116.74 on Monday. The company’s 50-day moving average is $121.75 and its 200-day moving average is $119.75. The firm has a market cap of $91.15 billion, a PE ratio of 43.84 and a beta of 1.74. Celgene has a 52 week low of $94.42 and a 52 week high of $127.64.
Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, April 27th. The biopharmaceutical company reported $1.68 EPS for the quarter, topping analysts’ consensus estimates of $1.47 by $0.21. The firm had revenue of $2.96 billion during the quarter, compared to the consensus estimate of $3.04 billion. Celgene had a net margin of 17.80% and a return on equity of 77.95%. The firm’s revenue was up 17.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.32 earnings per share. Analysts forecast that Celgene will post $7.28 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Canaccord Genuity Reiterates $156.00 Price Target for Celgene Co. (CELG)” was originally reported by sleekmoney and is the sole property of of sleekmoney. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://sleekmoney.com/canaccord-genuity-reiterates-156-00-price-target-for-celgene-co-celg/1854629.html.
In other news, Director Gilla Kaplan sold 14,033 shares of the company’s stock in a transaction dated Thursday, March 30th. The stock was sold at an average price of $123.83, for a total value of $1,737,706.39. Following the transaction, the director now owns 73,109 shares in the company, valued at approximately $9,053,087.47. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Rupert Vessey sold 4,000 shares of the company’s stock in a transaction dated Wednesday, March 1st. The shares were sold at an average price of $124.42, for a total value of $497,680.00. Following the completion of the transaction, the insider now owns 778 shares in the company, valued at approximately $96,798.76. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 27,283 shares of company stock worth $3,382,386. Corporate insiders own 0.97% of the company’s stock.
Institutional investors have recently modified their holdings of the stock. DUPONT CAPITAL MANAGEMENT Corp increased its position in shares of Celgene by 33.2% in the third quarter. DUPONT CAPITAL MANAGEMENT Corp now owns 217,205 shares of the biopharmaceutical company’s stock worth $22,704,000 after buying an additional 54,197 shares in the last quarter. Hellman Jordan Management Co. Inc. MA increased its position in shares of Celgene by 26.7% in the third quarter. Hellman Jordan Management Co. Inc. MA now owns 14,235 shares of the biopharmaceutical company’s stock worth $1,454,000 after buying an additional 3,000 shares in the last quarter. Rothschild Capital Partners LLC acquired a new position in shares of Celgene during the third quarter worth $4,386,000. Stratos Wealth Partners LTD. increased its position in shares of Celgene by 16.6% in the third quarter. Stratos Wealth Partners LTD. now owns 6,840 shares of the biopharmaceutical company’s stock worth $715,000 after buying an additional 972 shares in the last quarter. Finally, NEXT Financial Group Inc increased its position in shares of Celgene by 30.7% in the third quarter. NEXT Financial Group Inc now owns 5,920 shares of the biopharmaceutical company’s stock worth $619,000 after buying an additional 1,392 shares in the last quarter. Institutional investors own 77.68% of the company’s stock.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/canaccord-genuity-reiterates-156-00-price-target-for-celgene-co-celg/1854629.html
Receive News & Ratings for Celgene Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Co. and related companies with MarketBeat.com's FREE daily email newsletter.